A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- moderate to severe H.S. for at least 3 months

Exclusion Criteria:

- mild H.S. - women who are pregnant (or who are considering pregnancy) or breastfeeding

Conditions & Interventions

Conditions:
Dermatology (Skin, Hair & Nails), Rare Diseases
Keywords:
Hidradenitis Suppurativa(HS)

More Information

Description: We are studying a new drug, INCB054707, used to treat people who have hidradenitis suppurativa which is a chronic skin condition characterized by lumps or boils in places such as the armpits or groin. The skin lesions develop because of inflammation of the follicle. We are studying two doses of the drug and we will compare the effectiveness and side effects that occur. We will also have a group that receives an inactive medication (placebo). After the first 12 weeks of taking the drug or placebo, all participants will receive the active drug. The study will last for about 62 weeks.
Study Contact: Gretchen Bellefeuille - belle116@umn.edu
Principal Investigator: Noah Goldfarb
IRB Number: SITE00001790